Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07152002 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Study acronym: YHAA
StatusTerminated
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial terminated Sponsor's reason: Sponsor Decision Final enrollment: 77 participants (planned 144) · Primary completion date changed from estimate of Nov 2026 to Aug 26, 2026v9 Show all 3 changesShow less
    • Final enrollment: 77 participants (planned 144)
    • Primary completion date changed from estimate of Nov 2026 to Aug 26, 2026
  2. Enrollment closed, study ongoing Site details revised at 3 of 3 sitesv8 Show all 2 changesShow less
    • Site details revised at 3 of 3 sites
  3. Site details revised at 1 of 3 sitesv7
  4. Primary and study completion dates: Oct 2026 to Nov 2026 Site contacts updated at 2 of 3 sitesv6 Show all 2 changesShow less
    • Site contacts updated at 2 of 3 sites
  5. Site contacts updated at 1 of 3 sitesv5
Show 3 earlier versionsHide 3 earlier versions
  1. Site details revised at 1 of 3 sitesv4
  2. Site contacts updated at 1 of 3 sitesv3
  3. Site contacts updated at 1 of 3 sitesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
359 trials monitored
See 15 trials at risk
Obesity
3,560 trials monitored
See 142 trials at risk
The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Trial Details
NCT Number NCT07152002
Lead Sponsor Eli Lilly and Company
Conditions Overweight or Obesity, Healthy
Enrollment 77 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov